Michael Kluk, M.D., Ph.D., is the Director of Molecular and Genomic Pathology at Weill Cornell Medicine.  His focus is the integration of clinical pathology (especially molecular pathology and hematopathology) with biomedical research, and the application of these to the development and implementation of novel biomarkers.  Most recently, Dr. Kluk was involved in the development of an amplification-based next generation sequencing test to assess known mutations in over 90 genes of clinical significance in myeloid and lymphoid diseases.

Dr. Kluk graduated cum laude from the University of Rochester in 1995 with Bachelor of Arts degrees in Chemistry and French. He completed his M.D. and Ph.D. degrees at the University of Connecticut School of Medicine in 2004. He received Honors distinction for his Ph.D. thesis entitled: “Regulation of Vascular Smooth Muscle Cell Proliferation and Migration by Sphingosine-1-Phosphate”. Dr. Kluk then went on to complete his residency training in both Anatomic and Clinical Pathology at Yale New Haven Hospital from 2004-2008. Subsequently, he completed fellowship training in Hematopathology at Massachusetts General Hospital from 2008-2009 and fellowship training in Molecular Genetic Pathology at Brigham and Women’s Hospital (BWH) from 2009-2010. This was followed by a year as a post doctoral research fellow in the Department of Pathology at BWH (2010-2011). Dr. Kluk holds American Board of Pathology certification in Anatomic Pathology and Clinical Pathology and subspecialty certifications in Hematopathology and Molecular Genetic Pathology. He was appointed Instructor in Pathology at BWH and the Harvard Medical School in July 2011.